Table 1.
Baseline characteristics and clinical features of patients according to age category
| <55 yr (n=3034) | 55−64 yr (n=2699) | 65−74 yr (n=3329) | ≥75 yr (n=2206) | P Value | |
|---|---|---|---|---|---|
| Age (yr) | 46.7±6.0 | 59.7±2.9 | 69.5±2.9 | 79.7±4.0 | <0.001 |
| Men (%) | 2771 (91.4) | 2134 (79.2) | 2061 (62.0) | 1032 (46.8) | <0.001 |
| BMI (kg/m2) | 25.1±3.5 | 24.3±3.1 | 23.6±3.2 | 22.5±3.6 | <0.001 |
| Past History | |||||
| HTN | 1041 (34.4) | 1282 (47.6) | 1869 (56.4) | 1259 (57.3) | <0.001 |
| DM | 601 (19.9) | 800 (29.7) | 1111 (33.5) | 631 (28.7) | <0.001 |
| IHD | 325 (10.7) | 424 (15.7) | 617 (18.6) | 441 (20.1) | <0.001 |
| Hyperlipidemia | 357 (11.8) | 304 (11.3) | 282 (8.5) | 142 (6.5) | <0.001 |
| Smoking | 2429 (80.5) | 1678 (62.5) | 1605 (48.5) | 823 (37.6) | <0.001 |
| Initial presentation | |||||
| SBP | 130±28 | 129±29 | 128±29 | 126±31 | <0.001 |
| DBP | 82±25 | 79±17 | 77±16 | 75±18 | <0.001 |
| HR | 78±22 | 77±23 | 77±21 | 79±23 | 0.03 |
| Killip class | 1.3±0.7 | 1.4±0.8 | 1.5±0.9 | 1.7±1.0 | <0.001 |
| LVEF (%) | 53±11 | 52±12 | 51±13 | 49±13 | <0.001 |
| Diagnosis | <0.001 | ||||
| STEMI | 1949 (64.2) | 1617 (59.9) | 1864 (56.0) | 1198 (54.3) | |
| NSTEMI | 1085 (35.8) | 1082 (40.1) | 1465 (44.0) | 1008 (45.7) | |
| PCI | 2619 (86.5) | 2309 (85.7) | 2774 (83.5) | 1664 (75.6) | <0.001 |
| In-hospital mediation | |||||
| Aspirin | 2990 (99.1) | 2650 (98.7) | 3268 (98.7) | 2157 (98.1) | 0.03 |
| Clopidogrel | 2923 (96.9) | 2583 (96.5) | 3193 (96.4) | 2091 (95.1) | 0.01 |
| Anticoagulation | 2294 (76.0) | 2095 (78.0) | 2628 (79.4) | 1718 (78.2) | 0.01 |
| β-blocker | 2303 (76.3) | 1984 (73.9) | 2435 (73.5) | 1489 (67.7) | <0.001 |
| ACE inhibitor or ARB | 2467 (81.7) | 2152 (80.1) | 2666 (80.5) | 1710 (77.8) | 0.01 |
| Statin | 2298 (76.1) | 1996 (74.3) | 2411 (72.8) | 1512 (68.8) | <0.001 |
| Prevalence of CKD (ml/min per 1.73 m2) | |||||
| mean eGFR | 88.3±22.2 | 77.8±21.1 | 67.7±22.3 | 57.4±21.0 | <0.001 |
| <0.001 | |||||
| eGFR ≥60 | 2798 (92.2) | 2241 (83.0) | 2255 (67.7) | 1045 (47.4) | |
| eGFR 45−59 | 129 (4.3) | 284 (10.5) | 597 (17.9) | 526 (23.8) | |
| eGFR 30−44 | 32 (1.1) | 76 (2.8) | 249 (7.5) | 402 (18.2) | |
| eGFR <30 | 75 (2.5) | 98 (3.6) | 228 (6.8) | 233 (10.6) |
Data are presented as n (%) or mean ± SD. BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; SBP, systolic BP; DBP, diastolic BP; HR, heart rate; LVEF, left ventricular ejection fraction; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; eGFR, estimated GFR.